COVID-19 is an emerging, rapidly evolving siituation.

What people with cancer should know: https://www.cancer.gov/coronavirus

Guidance for cancer researchers: https://www.cancer.gov/coronavirus-researchers

Get the latest public health information from CDC: https://www.coronavirus.gov

Get the latest research information from NIH: https://www.nih.gov/coronavirus

News and Announcements

2025 | 2024 | 2023

Proteomics Measures Cancer Stemness and Identifies Therapeutic Targets

Researchers from the National Institute of Health’s Clinical Proteomic Tumor Analysis Consortium (CPTAC) and collaborating institutions have developed a novel protein expression-based stemness index (PROTsi) to evaluate oncogenic dedifferentiation in cancer. Their work, published in Cell Genomics, aims to quantify stem-like features in cancer which are closely linked to aggressive tumor behavior, resistance to therapies, and poor patient outcomes.…


Uncovering the Role of Germline Variants: A Proteogenomic Pan-Cancer Analysis

A new pan-cancer study from the National Institute of Health’s Clinical Proteomic Tumor Analysis Consortium (CPTAC) explores how inherited genetic variants shape protein function in cancer. Using a method called precision peptidomics, CPTAC researchers mapped over 337,000 coding germline variants to peptides detected in tumor samples and normal adjacent tissues across ten cancer types. Their work, published in Cell, has revealed how these variants might alter protein structure, allele-specific expression, post-translational modifications, and ultimately contribute to oncogenesis…


Advancing Precision Medicine Through Spatial Cancer Profiling

National Institutes of Health CPTAC researchers have uncovered new insights into tumor therapeutic resistance, heterogeneity, and immune evasion. Their work, published in Nature, leveraged several cutting-edge technologies, including spatial transcriptomics, single-nucleus RNA sequencing, and multiplexed imaging, to map the tumor microenvironment in unprecedented detail to understand how cells interact and how their location affects their behavior.…


Advancing Multiple Myeloma Research with Kiran Kumar Mangalaparthi, Ph.D.

The following is the eighth entry in a Q&A series highlighting selected Clinical Proteomic Tumor Analysis Consortium (CPTAC) researchers and their work. Join us as we discuss proteomic aspirations, the value of mentoring in science, and progress in multiple myeloma with Kiran Kumar Mangalaparthi, Ph.D., a Postdoctoral Researcher at Mayo Clinic in Rochester, Minnesota.…


Multiomics2Targets: Bridging Data and Discovery

Data analysis in proteogenomics has taken a marked step forward with the introduction of a new bioinformatics platform, Multiomics2Targets. This platform, developed by CPTAC researchers at the Icahn School of Medicine at Mount Sinai and published in Cell Reports Methods, integrates transcriptomics, proteomics, and phosphoproteomics data to identify potential therapeutic targets and is capable of generating detailed reports automatically. A companion protocol article describing how to use the system was also recently published in STAR Protocols.